Recent evidence suggests that sustained consumption of a high-fat diet is associated with reduced CB1 receptor expression in some brain areas. Many of the neuromodulatory functions of endogenous cannabinoids are mediated by the CB1 receptor. The CB1 receptor also mediates the behavioral and physiological effects of delta-9-tetrahydrocannabinol (delta-9-THC), the primary psychoactive constituent of marijuana. While high-fat diets are associated with region-specific changes in CB1 receptor expression, it is not clear whether such changes are behaviorally relevant. To that end, separate groups of male and female rats were placed on either a high-fat diet or a standard diet. Cannabinoid function was determined in a triad of measures (e.g., hypothermia, gross locomotion, time on bar apparatus) at postnatal day 30 (PD30), PD44, PD68 and PD114. These age points respectively correspond to rodent models of early adolescence, late adolescence, early adulthood and full maturity in humans. Male rats were also tested at PD37 and PD61. Subsequently, the antinociceptive properties of delta-9-THC and the effect of delta-9-THC on food intake were also measured. After 38 days, female rats maintained on a high-fat diet were significantly less sensitive to the psychomotor effects of delta-9-THC than were the female rats maintained on the control diet. These diet-related differences persisted into full maturity. Female rats maintained on a high-fat diet were also less sensitive to changes in food intake caused by delta-9-THC than were female rats maintained on the control diet. In contrast, the hypothermic effects of delta-9-THC were not differentially affected by the type of diet consumed. Likewise, female rats maintained on a high-fat diet exhibited tail-flick latencies that were indistinguishable from those of female rats maintained on the control diet. With two minor exceptions, and in sharp contrast to female rats, sensitivity to the pharmacological effects of delta-9-THC was not differentially affected by the type of diet in male rats. In short, female rats maintained on a high-fat diet appeared to be cross-tolerant to the psychomotor and hyperphagic effects of delta-9-THC while male rats maintained on a high-fat diet exhibited responses to delta-9-THC that were virtually indistinguishable from control animals.

The objectives were to investigate the effects of chromium (III) picolinate (CrPic; up to 2,000 ppb of Cr) on growing pigs subjected to a variety of stressors including thermal, immune, or dietary stress and to examine the effects of CrPic on steroidogenesis from adrenocortical cells. In the thermal stress study, high ambient temperature caused reduced weight gain and feed consumption (P andlt; 0.01), and low ambient temperature caused increased feed intake and feed:gain (P andlt; 0.01). However, these effects were not moderated by CrPic, and respiratory rate, plasma cortisol, or plasma glucose were unaffected by CrPic. In the immune stress study, pigs challenged with lipopolysaccharide (LPS) lost 951 g during 12 hours post injection, while the phosphate buffer saline (PBS) injected group gained 170 g (P andlt; 0.001). The LPS group showed higher rectal temperature (P andlt; 0.05), higher respiratory rate (P andlt; 0.05), greater plasma cortisol (P andlt; 0.001), and lower plasma glucose (P andlt; 0.05) than the PBS group. These effects were not ameliorated by CrPic. In the dietary stress study, pigs fed the high-fat diet (HFD) gained weight faster (P andlt; 0.05), consumed less feed (P andlt; 0.001), and had lower feed:gain (P andlt; 0.001). Plasma insulin concentration on d 14 decreased with CrPic (P andlt; 0.05) in a linear manner (P = 0.05). Consumption of the HFD resulted in increases of slaughter weight, perirenal fat, and back fat measurements (P andlt; 0.01). The CrPic resulted in linear reductions of carcass weight, last rib fat, last lumbar fat and average backfat (P andlt; 0.10). The effects of CrPic on carcass fat measurements were more significant in barrows than gilts. In the adrenocortical cell study, forskolin stimulated cortisol and DHEAs secretion from H295R cells. CrPic inhibited aspects of steroidogenesis in agonist-stimulated adrenocortical cells. Overall, dietary CrPic was unable to moderate the stress related effects due to high ambient temperature, low ambient temperature, or an endotoxin challenge. However, CrPic attenuated effects of HFD, mainly on body fat accretion of pigs, especially in barrows, and CrPic inhibited steroidogenesis in stimulated adrenocorticoid cells.

No description available.

L’hypothalamus est une aire cérébrale clé pour le contrôle de la prise alimentaire et des dépenses énergétiques ; en intégrant des signaux périphériques (hormones, nutriments). Une inflammation dans l’hypothalamus pourrait perturber le fonctionnement de ce dernier, dérégulant l’homéostasie énergétique et induire une perte de poids ou l’obésité. Nous avons cherché à identifier les relais moléculaires entre l’inflammation et les systèmes neuropeptidergiques hypothalamiques régulant l’homéostasie énergétique, en nous concentrant sur les chimiokines. D’une part, nous avons montré que le récepteur CCR2 participe à la perte de poids liée à une inflammation aigue induite chez la souris par l’injection centrale de lipopolysaccharide bactérien, possiblement en induisant l’inhibition de l’activité des neurones hypothalamiques à MCH, peptide aux effets orexigènes. D’autre part, nous avons étudié les liens entre inflammation hypothalamique, gain de poids et/ou la consommation de régimes hyperlipidiques pouvant induire à terme une obésité. Nous avons trouvé, chez la souris, que 1) la chimiokine CCL5 favoriserait la prise de poids, possiblement en activant les neurones hypothalamiques à MCH ; 2) la nature des lipides d’un régime hyperlipidique impacterait la cinétique de développement de l’obésité, avec des changements du profil inflammatoire et 3) la consommation excessive de lipides induirait une gliose très précoce dans l’hypothalamus. L’ensemble de nos résultats souligne l’intérêt de cibler l’inflammation hypothalamique dans ces pathologies et identifient les chimiokines comme cibles thérapeutiques potentielles dans le traitement des dérégulations de la balance énergétique. / The hypothalamus is a key brain region in the regulation of energy homeostasis, in particular by controlling food intake and energy storage and expenditure by integration of peripheral humoral and nutrient-related signals. Hypothalamic inflammation could alter hypothalamic function, thus deregulate energy homeostasis and induce weight-loss or obesity. We sought to identify mediators that could act as intermediaries between inflammation and neuropeptidergic systems of the hypothalamus that are involved in the regulation of energy homeostasis, focusing on chemokines. First, we studied the effect of a central injection of bacterial lipopolysaccharide, mimicking a acute and strong inflammation state in mice. We identified the receptor CCR2 as a central actor in the weight-loss induced by this treatment, possibly by direct inhibitory effects on hypothalamic neurons expressing MCH, a peptide known to have orexigenic and energy conservative effects. Second, we studied links between hypothalamic inflammation, weight-gain and/or high-fat diets consumption that can induce, eventually, obesity. We found in mice that: 1) the chemokine CCL5 would promote weight-gain, possibly by enhancing the activity of hypothalamic MCH neurons; 2) altering the lipid composition of a high-fat diet changes the kinetics of the development of diet-induced obesity, together with changes in the inflammatory profile and 3) an excessive dietary lipid intake can induce very early gliosis in the hypothalamus. Taken together, our results underline the interest of reducing hypothalamic inflammation to fight feeding behavior deregulations and identify chemokines as putative therapeutic targets.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / A obesidade e suas complicações metabólicas afetam o sistema endócrino e vários órgãos, tais como os testículos. Portanto, o objetivo deste estudo foi avaliar os efeitos da ingestão de diferentes dietas hiperlipídicas (rica em ácidos graxos saturados e/ou poliinsaturados) na massa corporal, no metabolismo de carboidratos e na morfologia testicular em ratos aos sete meses de idade. 39 ratos machos Wistar (três meses de idade) foram divididos em 4 grupos: SC (standard chow; n = 9), HF-S (dieta hiperlipídica rica em ácidos graxos saturados; n = 10), HF-P (dieta hiperlipídica rica em ácidos graxos poliinsaturados; n = 10), HF-SP (dieta hiperlipídica rica em ácidos graxos saturados e poliinsaturados; n = 10). A massa corporal foi monitorada semanalmente, até o final do experimento. Ao sacrifício (sete meses de idade), amostras de sangue foram coletadas e os testículos foram dissecados, pesados e processados para análises histomorfométrica, imunohistoquímica e bioquímica. Os depósitos de gordura genital foram dissecados e pesados. Os dados foram analisados por ANOVA e pós-teste de Bonferroni, considerando p < 0,05. As dietas hiperlipídicas promoveram aumento na massa corporal dos animais quando comparado ao grupo SC (p < 0,0001). Corroborando com esse resultado, os depósitos de gordura genital dos grupos hiperlipídicos (HF-S, HF-P e HF-SP) apresentaram aumento de 67%, 91% e 90% (p = 0,0004) em relação ao grupo SC, respectivamente. Quanto aos parâmetros séricos, os animais dos grupos HF-S e HF-SP apresentaram hiperglicemia (p = 0,0060), hiperinsulinemia (p = 0,0030), hipercolesterolemia (p = 0,0021). Todos os grupos hiperlipídicos apresentaram hiperleptinemia (p = 0,0019). Os níveis de triglicerídeos e testosterona não diferiram entre os grupos. Em relação ao testículo, os grupos SC, HF-P e HF-SP apresentaram maior altura do epitélio seminífero quando comparado ao grupo HF-S (p = 0,0003). No que diz respeito ao diâmetro dos túbulos seminíferos, verificou-se uma diminuição no grupo HF-SP, em comparação ao grupo SC (p = 0,0010). A proliferação celular foi reduzida no grupo HF-S comparado ao grupo SC (p = 0,0450). Não foram observadas diferenças na massa testicular e na concentração de colágeno. Diante do exposto, a administração de dieta HF, independentemente da qualidade do lipídio, promoveu o sobrepeso em ratos adultos. No entanto, a dieta rica em ácidos graxos saturados (banha de porco) promoveu alterações no metabolismo dos carboidratos e na morfologia testicular, com redução no diâmetro dos túbulos seminíferos, na altura do epitélio seminífero e na proliferação das células da linhagem espermatogênica. Estas alterações estão possivelmente relacionadas à distúrbios na espermatogênese. / Obesity and its metabolic complications affects the endocrine system and multiple organs such as the testes. This study aimed to evaluate the effects of different high-fat diets (rich in saturated and / or polyunsaturated fatty acids) on body mass, carbohydrate metabolism and testicular morphology in rats at seven months old. 39 male Wistar rats (three months old) were divided into four groups: SC (standard chow, n = 9), HF-S (high fat diet rich in saturated fatty acids, n = 10), HF-P (high fat diet rich in polyunsaturated fatty acids, n = 10), HF-SP (high fat diet rich in saturated and polyunsaturated fatty acids, n = 10). Body mass was monitored weekly until the end of the experiment. At the sacrifice (seven months old), blood samples were collected and the testes were dissected, weighed and processed for histomorphometrical, immunohistochemical and biochemical analysis. Genital fat deposits were dissected and weighed. Data were analyzed by one-way ANOVA and Bonferroni post hoc test, considering p < 0.05. Different high-fat diets promoted an increased in body mass compared with the SC group (p < 0.0001). Accordingly, the genital fat deposits were higher in the high-fat groups (HF-S, HF-P, HF-SP) than in the SC group, showing an increase of 67%, 91% and 90%, respectively (p = 0.0004). Regarding serum parameters, the animals in the HF-S and HF-SP groups presented hyperglycemia (p = 0.0060), hyperinsulinemia (p = 0.0030), hypercholesterolemia (p = 0.0021). All of the hyperlipidemic groups showed hyperleptinemia (p = 0.0019). Serum triglyceride and serum testosterone levels did not differ among the groups. Concerning the testis, the SC, HF-P and HF-SP groups showed an increase on seminiferous epithelium height compared with the HF-S group (p = 0.0003). As the seminiferous tubule diameter, there was a decrease in the HF-SP group in comparison with the SC group (p = 0.0010). Cell proliferation was reduced in HF-S group compared with the SC group (p = 0.0450). Among the groups, no difference was observed in the testicular mass and in collagen level. In conclusion, the high fat diet administration, independent of the lipid quality, promotes overweight. Diet rich in saturated fatty acids (lard) alters the carbohydrate metabolism and the testicular morphology with reductions of seminiferous epithelium height, seminiferous tubule diameter and cell proliferation which could be related to a disturbance of spermatogenesis.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / A obesidade e suas complicações metabólicas afetam o sistema endócrino e vários órgãos, tais como os testículos. Portanto, o objetivo deste estudo foi avaliar os efeitos da ingestão de diferentes dietas hiperlipídicas (rica em ácidos graxos saturados e/ou poliinsaturados) na massa corporal, no metabolismo de carboidratos e na morfologia testicular em ratos aos sete meses de idade. 39 ratos machos Wistar (três meses de idade) foram divididos em 4 grupos: SC (standard chow; n = 9), HF-S (dieta hiperlipídica rica em ácidos graxos saturados; n = 10), HF-P (dieta hiperlipídica rica em ácidos graxos poliinsaturados; n = 10), HF-SP (dieta hiperlipídica rica em ácidos graxos saturados e poliinsaturados; n = 10). A massa corporal foi monitorada semanalmente, até o final do experimento. Ao sacrifício (sete meses de idade), amostras de sangue foram coletadas e os testículos foram dissecados, pesados e processados para análises histomorfométrica, imunohistoquímica e bioquímica. Os depósitos de gordura genital foram dissecados e pesados. Os dados foram analisados por ANOVA e pós-teste de Bonferroni, considerando p < 0,05. As dietas hiperlipídicas promoveram aumento na massa corporal dos animais quando comparado ao grupo SC (p < 0,0001). Corroborando com esse resultado, os depósitos de gordura genital dos grupos hiperlipídicos (HF-S, HF-P e HF-SP) apresentaram aumento de 67%, 91% e 90% (p = 0,0004) em relação ao grupo SC, respectivamente. Quanto aos parâmetros séricos, os animais dos grupos HF-S e HF-SP apresentaram hiperglicemia (p = 0,0060), hiperinsulinemia (p = 0,0030), hipercolesterolemia (p = 0,0021). Todos os grupos hiperlipídicos apresentaram hiperleptinemia (p = 0,0019). Os níveis de triglicerídeos e testosterona não diferiram entre os grupos. Em relação ao testículo, os grupos SC, HF-P e HF-SP apresentaram maior altura do epitélio seminífero quando comparado ao grupo HF-S (p = 0,0003). No que diz respeito ao diâmetro dos túbulos seminíferos, verificou-se uma diminuição no grupo HF-SP, em comparação ao grupo SC (p = 0,0010). A proliferação celular foi reduzida no grupo HF-S comparado ao grupo SC (p = 0,0450). Não foram observadas diferenças na massa testicular e na concentração de colágeno. Diante do exposto, a administração de dieta HF, independentemente da qualidade do lipídio, promoveu o sobrepeso em ratos adultos. No entanto, a dieta rica em ácidos graxos saturados (banha de porco) promoveu alterações no metabolismo dos carboidratos e na morfologia testicular, com redução no diâmetro dos túbulos seminíferos, na altura do epitélio seminífero e na proliferação das células da linhagem espermatogênica. Estas alterações estão possivelmente relacionadas à distúrbios na espermatogênese. / Obesity and its metabolic complications affects the endocrine system and multiple organs such as the testes. This study aimed to evaluate the effects of different high-fat diets (rich in saturated and / or polyunsaturated fatty acids) on body mass, carbohydrate metabolism and testicular morphology in rats at seven months old. 39 male Wistar rats (three months old) were divided into four groups: SC (standard chow, n = 9), HF-S (high fat diet rich in saturated fatty acids, n = 10), HF-P (high fat diet rich in polyunsaturated fatty acids, n = 10), HF-SP (high fat diet rich in saturated and polyunsaturated fatty acids, n = 10). Body mass was monitored weekly until the end of the experiment. At the sacrifice (seven months old), blood samples were collected and the testes were dissected, weighed and processed for histomorphometrical, immunohistochemical and biochemical analysis. Genital fat deposits were dissected and weighed. Data were analyzed by one-way ANOVA and Bonferroni post hoc test, considering p < 0.05. Different high-fat diets promoted an increased in body mass compared with the SC group (p < 0.0001). Accordingly, the genital fat deposits were higher in the high-fat groups (HF-S, HF-P, HF-SP) than in the SC group, showing an increase of 67%, 91% and 90%, respectively (p = 0.0004). Regarding serum parameters, the animals in the HF-S and HF-SP groups presented hyperglycemia (p = 0.0060), hyperinsulinemia (p = 0.0030), hypercholesterolemia (p = 0.0021). All of the hyperlipidemic groups showed hyperleptinemia (p = 0.0019). Serum triglyceride and serum testosterone levels did not differ among the groups. Concerning the testis, the SC, HF-P and HF-SP groups showed an increase on seminiferous epithelium height compared with the HF-S group (p = 0.0003). As the seminiferous tubule diameter, there was a decrease in the HF-SP group in comparison with the SC group (p = 0.0010). Cell proliferation was reduced in HF-S group compared with the SC group (p = 0.0450). Among the groups, no difference was observed in the testicular mass and in collagen level. In conclusion, the high fat diet administration, independent of the lipid quality, promotes overweight. Diet rich in saturated fatty acids (lard) alters the carbohydrate metabolism and the testicular morphology with reductions of seminiferous epithelium height, seminiferous tubule diameter and cell proliferation which could be related to a disturbance of spermatogenesis.

Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro / A intervenção farmacológica pode minimizar ou até mesmo reverter o remodelamento adverso em órgãos num modelo de síndrome metabólica. Este trabalho teve como objetivo avaliar os efeitos das monoterapias e associações medicamentosas sobre a morfologia do tecido adiposo, remodelamento hepático e pancreático em camundongos C57bl/6 alimentados com dieta very high-fat. Camundongos C57bl/6 machos foram alimentados com dieta very high-fat (HF, 60% de lipídios) ou dieta padrão (SC, 10% de lipídios) por 10 semanas, quando foram iniciados os tratamentos: HF-T (HF + Telmisartana, 5.2mg/Kg/dia), HF-S (HF + Sitagliptina, 1.08g/Kg/dia), HF-M (HF + Metformina, 310.0mg/Kg/dia) e as associações medicamentosas HF-TM, HF-TS e HF-SM. Os grupos tratados também tiveram livre acesso à dieta high fat e os tratamentos duraram 6 semanas. Técnicas morfométricas, estereológicas, imunohistoquímicas, ELISA, western blotting e microscopia eletrônica foram utilizadas. A dieta high-fat causou sobrepeso, intolerância oral à glucose, hiperinsulinemia, hipertrofia de ilhotas e adipócitos, grau 2 de esteatose hepatica (<33%) redução da expressão de PPAR-alfa e de GLUT-2, concomitante com aumento da expressão de SREBP-1 no grupo HF (P<0.0001). Por outro lado, todos os tratamentos resultaram em perda de peso significativa, reversão da resistência à insulina, hipertrofia de ilhotas e adipócitos e alívio da esteatose hepática. Somente os grupos HF-T e HF-TS apresentaram massa corporal similar ao grupo SC ao final do experimento, sendo que o ultimo também apresentou reversão da esteatose hepática. O aumento da expressão do PPAR-alfa paralelamente ao decréscimo da expressão do SREBP-1 explica os achados favoráveis para o fígado. A normalização do tamanho do adipócito foi consistente com os níveis maiores de adiponectina e com a redução dos níveis de TNF-alfa (P<0.0001) nos grupos tratados.Todos os tratamentos foram eficazes para controlar a síndrome metabólica. Os melhores resultados foram alcançados com a telmisartana e sitagliptina como monoterapias ou como associação entre essas, combinando a ativação parcial do PPAR-alfa no fígado com a extensão do tempo de ação das incretinas / Pharmacological intervention can minimize or even reverse adverse remodeling due to metabolic syndrome. This work sought to evaluate the effects of monotherapies and combinations of drugs on insulin sensitivity, adipose tissue morphology, pancreatic and hepatic remodelling in C57BL/6 mice fed a high-fat diet. Male C57BL/6 mice were fed a very high-fat diet (HF, 60% lipids) or standard chow (SC, 10% lipids) over 10 weeks, after which drug treatments began: HF-T (HF + Telmisartan, 5.2mg/Kg/day), HF-S (HF + Sitagliptin, 1.08g/Kg/day), HF-M (HF + Metformin, 310.0mg/Kg/day) and the drug combinations HF-TM, HF-TS and HF-SM. Treated groups also had free access to HF diet and treatments lasted 6 weeks. Morphometry, stereological tools, immunostaining, ELISA, Western blotting and electron microscopy were used. The HF diet yielded an overweight phenotype, oral glucose intolerance, hyperinsulinemia, hypertrophied islets and adipocytes, stage 2 steatosis (<33%) and reduced liver PPAR-alpha and GLUT-2, concomitant with enhanced SREBP-1 expression, in the HF group (P<0.0001). Conversely, all drug treatments resulted in significant weight loss, reversed insulin resistance, islet and adipocyte hypertrophy and alleviated hepatic steatosis. Only HF-T and HF-TS presented body weights similar to SC mice at the end of the experiment and the latter treatment reversed hepatic steatosis. Increased PPAR-alpha immunostaining parallel to higher GLUT-2 and reduced SREBP-1 expression explain the favourable hepatic outcomes. Restoration of adipocyte size was consistent with higher adiponectin levels and lower TNF-alpha levels (P<0.0001) in treated groups. In conclusion, all treatments were effective in controlling metabolic syndrome. The best results were achieved using Telmisartan and Sitagliptin as monotherapies or as a dual treatment, combining partial PPAR-gamma agonism and PPAR-alpha activation in the liver with extended incretin action

Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro / A intervenção farmacológica pode minimizar ou até mesmo reverter o remodelamento adverso em órgãos num modelo de síndrome metabólica. Este trabalho teve como objetivo avaliar os efeitos das monoterapias e associações medicamentosas sobre a morfologia do tecido adiposo, remodelamento hepático e pancreático em camundongos C57bl/6 alimentados com dieta very high-fat. Camundongos C57bl/6 machos foram alimentados com dieta very high-fat (HF, 60% de lipídios) ou dieta padrão (SC, 10% de lipídios) por 10 semanas, quando foram iniciados os tratamentos: HF-T (HF + Telmisartana, 5.2mg/Kg/dia), HF-S (HF + Sitagliptina, 1.08g/Kg/dia), HF-M (HF + Metformina, 310.0mg/Kg/dia) e as associações medicamentosas HF-TM, HF-TS e HF-SM. Os grupos tratados também tiveram livre acesso à dieta high fat e os tratamentos duraram 6 semanas. Técnicas morfométricas, estereológicas, imunohistoquímicas, ELISA, western blotting e microscopia eletrônica foram utilizadas. A dieta high-fat causou sobrepeso, intolerância oral à glucose, hiperinsulinemia, hipertrofia de ilhotas e adipócitos, grau 2 de esteatose hepatica (<33%) redução da expressão de PPAR-alfa e de GLUT-2, concomitante com aumento da expressão de SREBP-1 no grupo HF (P<0.0001). Por outro lado, todos os tratamentos resultaram em perda de peso significativa, reversão da resistência à insulina, hipertrofia de ilhotas e adipócitos e alívio da esteatose hepática. Somente os grupos HF-T e HF-TS apresentaram massa corporal similar ao grupo SC ao final do experimento, sendo que o ultimo também apresentou reversão da esteatose hepática. O aumento da expressão do PPAR-alfa paralelamente ao decréscimo da expressão do SREBP-1 explica os achados favoráveis para o fígado. A normalização do tamanho do adipócito foi consistente com os níveis maiores de adiponectina e com a redução dos níveis de TNF-alfa (P<0.0001) nos grupos tratados.Todos os tratamentos foram eficazes para controlar a síndrome metabólica. Os melhores resultados foram alcançados com a telmisartana e sitagliptina como monoterapias ou como associação entre essas, combinando a ativação parcial do PPAR-alfa no fígado com a extensão do tempo de ação das incretinas / Pharmacological intervention can minimize or even reverse adverse remodeling due to metabolic syndrome. This work sought to evaluate the effects of monotherapies and combinations of drugs on insulin sensitivity, adipose tissue morphology, pancreatic and hepatic remodelling in C57BL/6 mice fed a high-fat diet. Male C57BL/6 mice were fed a very high-fat diet (HF, 60% lipids) or standard chow (SC, 10% lipids) over 10 weeks, after which drug treatments began: HF-T (HF + Telmisartan, 5.2mg/Kg/day), HF-S (HF + Sitagliptin, 1.08g/Kg/day), HF-M (HF + Metformin, 310.0mg/Kg/day) and the drug combinations HF-TM, HF-TS and HF-SM. Treated groups also had free access to HF diet and treatments lasted 6 weeks. Morphometry, stereological tools, immunostaining, ELISA, Western blotting and electron microscopy were used. The HF diet yielded an overweight phenotype, oral glucose intolerance, hyperinsulinemia, hypertrophied islets and adipocytes, stage 2 steatosis (<33%) and reduced liver PPAR-alpha and GLUT-2, concomitant with enhanced SREBP-1 expression, in the HF group (P<0.0001). Conversely, all drug treatments resulted in significant weight loss, reversed insulin resistance, islet and adipocyte hypertrophy and alleviated hepatic steatosis. Only HF-T and HF-TS presented body weights similar to SC mice at the end of the experiment and the latter treatment reversed hepatic steatosis. Increased PPAR-alpha immunostaining parallel to higher GLUT-2 and reduced SREBP-1 expression explain the favourable hepatic outcomes. Restoration of adipocyte size was consistent with higher adiponectin levels and lower TNF-alpha levels (P<0.0001) in treated groups. In conclusion, all treatments were effective in controlling metabolic syndrome. The best results were achieved using Telmisartan and Sitagliptin as monotherapies or as a dual treatment, combining partial PPAR-gamma agonism and PPAR-alpha activation in the liver with extended incretin action